Education
About Us
Working with TipRanks
Follow Us
Enovis (ENOV)
NYSE:ENOV
ENOV Stock Chart & Stats
$30.31
$0.83(1.85%)
At close: 4:00 PM EST
$30.31
$0.83(1.85%)
Day’s Range― - ―
52-Week Range$25.47 - $49.75
Previous CloseN/A
Volume391.51K
Average Volume (3M)810.95K
Market Cap
$1.73B
Enterprise Value$3.24B
Total Cash (Recent Filing)$33.62M
Total Debt (Recent Filing)$1.44B
Price to Earnings (P/E)―
Beta1.39
Next Earnings
Feb 19, 2026EPS Estimate
0.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.75
Shares Outstanding57,189,380
10 Day Avg. Volume760,909
30 Day Avg. Volume810,954
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.95
Price to Sales (P/S)1.15
P/FCF Ratio-36.09
Enterprise Value/Market Cap1.87
Enterprise Value/Revenue1.45
Enterprise Value/Gross Profit2.49
Enterprise Value/Ebitda-3.28
Forecast
1Y Price Target
$49.00Price Target Upside61.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)3.19
Revenue Forecast (FY)$2.26B
Bulls Say, Bears Say
Bulls Say
EarningsEnovis reported a solid Q3, with 9% reported growth including 12% growth in Recon and 6% growth for P&R.
Financial PerformanceEnovis raised its FY25 aEBITDA and EPS expectations, supported by operational execution, FX tailwinds, and a more favorable tariff outlook.
ValuationThe stock is trading at less than half the valuation of its small-cap MedTech peers, suggesting it is significantly undervalued.
Bears Say
Growth OutlookStock weakness is due to noise in hip/knees and reiterated organic growth implying a step down in fourth-quarter organic growth.
Management GuidanceManagement is suspected to be providing conservative guidance, with execution on upside needed to provide relief to the stock.
Revenue GuidanceManagement lowered revenue guidance due to the Dr. Comfort divestiture.
Enovis News
ENOV FAQ
What was Enovis’s price range in the past 12 months?
Enovis lowest stock price was $25.46 and its highest was $49.75 in the past 12 months.
What is Enovis’s market cap?
Enovis’s market cap is $1.73B.
When is Enovis’s upcoming earnings report date?
Enovis’s upcoming earnings report date is Feb 19, 2026 which is in 83 days.
How were Enovis’s earnings last quarter?
Enovis released its earnings results on Nov 06, 2025. The company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.649 by $0.101.
Is Enovis overvalued?
According to Wall Street analysts Enovis’s price is currently Undervalued.
Does Enovis pay dividends?
Enovis does not currently pay dividends.
What is Enovis’s EPS estimate?
Enovis’s EPS estimate is 0.81.
How many shares outstanding does Enovis have?
Enovis has 57,189,380 shares outstanding.
What happened to Enovis’s price movement after its last earnings report?
Enovis reported an EPS of $0.75 in its last earnings report, beating expectations of $0.649. Following the earnings report the stock price went down -9.749%.
Which hedge fund is a major shareholder of Enovis?
Currently, no hedge funds are holding shares in ENOV
Enovis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$49.00 (61.66% Upside)
$49.00 (61.66% Upside)
Blogger Sentiment
Bullish
ENOV Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $200.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 8.5%
Last 30 Days ▼ 8.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-36.51%
12-Months-Change
Fundamentals
Return on Equity
-51.11%
Trailing 12-Months
Asset Growth
-20.12%
Trailing 12-Months
Company Description
Enovis
Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.
ENOV Company Deck
ENOV Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects strong revenue growth, improved gross margins, and positive steps in innovation, particularly in international markets and the Arvis Ultra launch. However, the goodwill impairment and the impacts of tariffs and divestitures present significant challenges.View all ENOV earnings summariesENOV Stock 12 Month Forecast
Average Price Target
$49.00
▲(61.66% Upside)
Technical Analysis
Enerpac Tool Group
―
Hillenbrand
―
Standex International
―
Helios Technologies
―
Xometry
―
Ownership Overview
Currently, No data available
---